Physician profile
Mary E Hurley
NPI 1316057748
$6,214.79
in general payments reported to CMS, 2019-2025
24 companies · $616 in 2025
The $616 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $463 · 2021: $1,030 · 2022: $1,036 · 2023: $1,243 · 2024: $634 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,397.43 | 2019-2025 | |
| Merz North America, INC. | $965.13 | 2019-2024 | |
| Allergan, INC. | $869.34 | 2019-2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $696.21 | 2023 | |
| Galderma Laboratories, L.P. | $508.57 | 2019-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $461.68 | 2019-2025 | Adbry |
| Genzyme Corporation | $430.45 | 2020-2025 | |
| Organon LLC | $133.34 | 2025 | Vtama |
| Amgen INC. | $109.26 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $105.53 | 2022-2025 | |
| Lilly USA, LLC | $101.54 | 2020-2025 | Ebglyss |
| Pfizer INC. | $82.10 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $61.62 | 2019-2022 | |
| Biofrontera INC. | $57.10 | 2019-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Sun Pharmaceutical Industries INC. | $46.86 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $37.52 | 2021 | |
| Integra Lifesciences Corporation | $28.73 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Azurity Pharmaceuticals, INC. | $23.79 | 2025 | Horizant |
| Journey Medical Corporation | $20.83 | 2022 | |
| Incyte Corporation | $20.57 | 2025 | Opzelura |
| Encore Dermatology INC. | $16.82 | 2019 | |
| Krystal Biotech INC | $15.93 | 2023 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.56 | 2021 | |
| Medtronic, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.